Business Context and Reporting Period
Company: Clearmind Medicine Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 26, 2025
Context: The Company announced a definitive securities purchase agreement for a registered direct offering to raise capital for general corporate purposes, including research and development.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Common Shares Issued | 7,944,868 |
| Pre-Funded Warrants Issued | 2,865,960 (exercisable for Common Shares) |
| Price per Common Share | $0.12 |
| Price per Pre-Funded Warrant | $0.1199 |
| Expected Gross Proceeds | Approximately $1.294 million |
| Exercise Price (Pre-Funded Warrants) | $0.0001 per share |
Liquidity and Debt: The filing does not provide current cash balances, debt levels, or operating cash flow figures. Proceeds are intended to supplement existing cash for working capital and capital expenditures.
Material Changes and Transaction Structure
- Capital Raise: The Company is executing a registered direct offering expected to close on or about November 26, 2025.
- Instrument Structure: The offering includes common shares and pre-funded warrants. The warrants are immediately exercisable on a cashless basis.
- Ownership Limitation: Holders cannot exercise warrants if doing so would result in beneficial ownership exceeding 4.99% of outstanding shares immediately post-exercise.
- Registration: Securities are issued under a takedown from an effective shelf registration statement (Form F-3, File No. 333-275991).
Outlook, Risks, and Management Commentary
Use of Proceeds: Net proceeds will be used for general corporate purposes, specifically operating expenses, research and development (clinical and pre-clinical testing), working capital, future acquisitions, and capital expenditures.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to customary closing conditions; failure to satisfy these may prevent the offering from closing.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the closing date and use of funds, which are not guaranteed and subject to risks beyond the Company's control.
Investor Verification Checklist
- Verify the final closing date of the offering, as it is currently expected but not guaranteed.
- Confirm the exact number of shares outstanding post-offering to assess dilution impact.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Check the Company's most recent audited financial statements for current cash position and burn rate, as this filing does not provide them.